Need Help? Chat Now With a Live Representative!

ARG successfully starts up a Phase II trial within 6 weeks

ARG successfully starts up a Phase II trial within 6 weeks

ARG successfully starts up a Phase II trial within 6 weeks

May 1, 2018

Challenge:

In an economic downturn, small biotech companies often depend on clinical milestones in order to maximize shareholder value and drive market direction. This means that their CRO must completely understand and be aligned with the sponsor’s corporate objectives. Meeting an aggressive timeline on a challenging protocol is a significant driver of share price and market perception.

Results:

ARG successfully started a Phase II intradialytic hypotension trial and enrolled the first patient within 6 weeks of contract signature. Using TrialVista®, ARG’s proprietary CTMS, the implementation of all study start–up activities, from investigator recruitment to investigator product supply, was streamlined — and, based on its advanced approach to project management, several steps were significantly reduced or even eliminated.

ARG was able to simultaneously get all the trial materials developed, finalize CRF design and collaborate with qualified investigators to ensure FPI (first patient in) deadlines were achieved ahead of schedule.

ARG has been ahead of every study metric since the FPI deadline and completed enrollment on this 15 center, 75 patient trial on time and on budget.

Lessons Learned

It is critical that your CRO understands the corporate goals of its sponsors and adjusts their resources to meet the demands of the study. Aggressive timelines are some times unrealistic, but at ARG we thoroughly evaluate each component, apply the best and correct amount of resources needed to meet or exceed our client’s needs.

By utilizing TrialVista®, and ARG’s experienced clinical management team, sponsors are ensured of several things:

  • Rapid Implementation
  • Total Team Involvement
  • Precise Monitoring of Key Trial Parameters
  • 24/7/365 Support
  • Clinical Operations Manager & Product Development:

"ARG was able to go from contract to enrolling the first patient in an incredibly short period of time. We are extremely pleased to be working with them on this trial and are excited about being able to utilize TrialVista® throughout this study”

Preferred Provider Status for Atlantic Research Group

Preferred Provider Status for Atlantic Research Group

Challenge: A specialty biopharmaceutical company targeting the therapeutic power of plasma for the treatment of chronic, life-altering diseases like hemophilia […]

February 1, 2018
ARG rescues Phase I oncology trial using TrialVista® CTMS

ARG rescues Phase I oncology trial using TrialVista® CTMS

Challenge: A leading specialty pharmaceutical company focused on the development and commercialization of next generation therapies for cancer and immunomodulatory […]

March 1, 2018
Pivotal Phase III trial undergoes audits by the FDA and sponsor

Pivotal Phase III trial undergoes audits by the FDA and sponsor

Challenge: A pivotal Phase III clinical trial of C1 inhibitor for the prophylactic treatment of hereditary angioedema managed by ARG […]

June 1, 2018
GO TO TOP